Get the Stockscreener App
9.09
2.47%
-0.23
Vir Biotechnology Inc stock is traded at $9.09, with a volume of 5.34M.
It is down -2.47% in the last 24 hours and up +18.21% over the past month.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
See More
Previous Close:
$9.32
Open:
$9.29
24h Volume:
5.34M
Relative Volume:
1.88
Market Cap:
$1.26B
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-2.3189
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
+20.24%
1M Performance:
+18.21%
6M Performance:
+73.80%
1Y Performance:
+12.08%
1-Day Range:
$8.89
$9.50
1-Week Range:
$7.26
$10.94
52-Week Range:
$4.155
$10.94
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.09 | 1.30B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Leerink raises Vir Biotechnology stock price target on partnership - Investing.com
Vir Biotechnology (NASDAQ:VIR) Shares Gap DownShould You Sell? - MarketBeat
Vir Biotechnology (VIR) Earnings Call Transcript - AOL.com
Vir Biotechnology Prices $150 Mln Public Offering At $8.50 Per Share, Stock Down - Nasdaq
Vir Biotechnology prices $150M stock offering at $8.50/share By Investing.com - Investing.com Nigeria
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology stock tumbles on discounted share offering By Investing.com - Investing.com India
Vir Biotechnology announces pricing of public offering of common stock at $8.50 per share - marketscreener.com
Vir Biotechnology (VIR) Prices Public Offering at $8.50 Per Shar - GuruFocus
Vir Biotechnology Announces Pricing of Public Offering of Common Stock - PharmiWeb.com
Vir Biotechnology launches $200M public stock offering - MSN
Vir Biotechnology prices $150M stock offering at $8.50/share - Investing.com
[144] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Vir Biotechnology Extends Reach with Astellas Collaboration on VIR-5500 - StocksToTrade
Vir Biotechnology leaps on news of Astellas collaboration - The Pharma Letter
Vir Biotechnology (VIR) Receives Maintained Overweight Rating Fr - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Vir Biotechnology plans $200 million stock offering - Investing.com India
Vir Biotechnology Announces Proposed Public Offering of Common Stock - BioSpace
A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update - Yahoo Finance
Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,089 Shares of Stock - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CEO Sells 19,039 Shares of Stock - MarketBeat
Verneuil Vanina De Sells 4,445 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 2,089 Shares of Stock - MarketBeat
Aug Big Picture: Can Vir Biotechnology Inc be recession proofJuly 2025 Chart Watch & AI Based Trade Execution Alerts - baoquankhu1.vn
Assessing Vir Biotechnology (VIR) Valuation After A Strong Year To Date Share Price Rebound - simplywall.st
VIR: Needham Raises Vir Biotechnology's Price Target in New Anal - GuruFocus
Vir Biotechnology’s Call Highlights Astellas Deal, VIR-5500 Momentum - TipRanks
These Stocks Are Today’s Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More - Barron's
VIR Stock Offering Managed by Leading Financial Firms - GuruFocus
Astellas, Vir Biotechnology form partnership on prostate cancer drug By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week high at 9.88 USD By Investing.com - Investing.com South Africa
Vir Biotechnology plans $200 million stock offering By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) Stock Surges to 52-Week High on Astellas Deal and Strong Earnings - MEXC
This Small-Cap Biotech Stock Is Soaring 29%. There’s Excitement Over Its Prostate Cancer Drug. - Barron's
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - The Malaysian Reserve
Morgan Stanley Raises Price Target for VIR to $24 with Overweigh - GuruFocus
Vir Biotechnology: Up On Prostate Data And Astellas DealI'm (Long-Term) Bullish (VIR) - Seeking Alpha
These Analysts Boost Their Forecasts On Vir Biotechnology - Benzinga
Vir Biotechnology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Astellas and Vir in $1.3B deal for CD3 T-cell engager - bioworld.com
Vir Biotechnology, Inc. Q4 & Full Year 2025 Earnings: Revenue Hits $64.1M on Norgine Deal - Bayelsa Watch
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug - Barron's
VIR: Evercore ISI Group Raises Price Target to $18, Maintains Ou - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High After Earnings Beat - MarketBeat
Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN - Pharmaceutical Executive
Biotech and Big Tech Drive the Morning Narrative (2026-02-24) - Seeking Alpha
Henry Schein, Vir Biotechnology, Ultra Clean Holdings And Other Big Stocks Moving Higher On Tuesday - Benzinga
Vir Biotechnology stock hits 52-week high at 9.88 USD - Investing.com Nigeria
Vir Biotechnology Secures New Collaboration and Revenue Surge - StocksToTrade
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vir Biotechnology Inc Stock (VIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SATO VICKI L | Director |
Feb 24 '26 |
Sale |
9.75 |
42,377 |
413,366 |
1,144,391 |
| Sabatini Brent | SVP, Chief Accounting Officer |
Feb 24 '26 |
Sale |
9.53 |
1,430 |
13,632 |
69,613 |
| O'Byrne Jason | EVP & Chief Financial Officer |
Feb 24 '26 |
Sale |
9.53 |
1,634 |
15,576 |
162,615 |
| Eisner Mark | EVP and Chief Medical Officer |
Feb 25 '26 |
Sale |
9.82 |
1,889 |
18,550 |
154,024 |
| Eisner Mark | EVP and Chief Medical Officer |
Feb 24 '26 |
Sale |
9.53 |
1,616 |
15,405 |
155,913 |
| de Verneuil Vanina | EVP, General Counsel, Corp Sec |
Feb 25 '26 |
Sale |
9.82 |
13,700 |
134,534 |
112,982 |
| de Verneuil Vanina | EVP, General Counsel, Corp Sec |
Feb 24 '26 |
Sale |
9.53 |
3,117 |
29,713 |
126,682 |
| De Backer Marianne | Chief Executive Officer |
Feb 24 '26 |
Sale |
9.53 |
14,762 |
140,720 |
1,020,704 |
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):